Analysts Just Made A Massive Upgrade To Their Ryvu Therapeutics S.A. (WSE:RVU) Forecasts
Ryvu Therapeutics S.A. (WSE:RVU) shareholders will have a reason to smile today, with the analysts making substantial upgrades to next year's forecasts. Consensus estimates suggest investors could expect greatly increased statutory revenues and earnings per share, with analysts modelling a real improvement in business performance.
Following the upgrade, the current consensus from Ryvu Therapeutics' four analysts is for revenues of zł162m in 2026 which - if met - would reflect a sizeable 79% increase on its sales over the past 12 months. The loss per share is anticipated to greatly reduce in the near future, narrowing 91% to zł0.46. However, before this estimates update, the consensus had been expecting revenues of zł116m and zł2.89 per share in losses. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven.
Check out our latest analysis for Ryvu Therapeutics
There was no major change to the consensus price target of zł43.53, perhaps suggesting that the analysts remain concerned about ongoing losses despite the improved earnings and revenue outlook.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's clear from the latest estimates that Ryvu Therapeutics' rate of growth is expected to accelerate meaningfully, with the forecast 59% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 27% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 9.2% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Ryvu Therapeutics is expected to grow much faster than its industry.
The Bottom Line
The most important thing here is that analysts reduced their loss per share estimates for next year, reflecting increased optimism around Ryvu Therapeutics' prospects. Fortunately, analysts also upgraded their revenue estimates, and our data indicates sales are expected to perform better than the wider market. The lack of change in the price target is puzzling, but with a serious upgrade to next year's earnings expectations, it might be time to take another look at Ryvu Therapeutics.
Better yet, Ryvu Therapeutics is expected to break-even soon - within the next few years - according to analyst forecasts, which would be a momentous event for shareholders. For more information, you can click through to our free platform to learn more about these forecasts.
Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.